![]()
Delivering therapeutic progenitor cells are an attractive method to stimulate regeneration in spinal cord or heart injuries. Many companies have approached clinical trials for the use of stem cell therapy, but are faced with a major hurdle in administration. Delivering cells into the human body with traditional injection methods results in poor cell survival and retention. Cells are particularly vulnerable to shear stress, whereby the cells are damaged during injection and therefore may not effectively integrate into the host tissue to rejuvenate a population of cells. This delivery dilemma needs to be addressed in order to move forward with stem cell therapeutics.
